MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (NCT06586515)

🧪 Interventions in This Study

• LY3962673 (DRUG)
• Cetuximab (DRUG)
• Gemcitabine (DRUG)
• nab-paclitaxel (DRUG)
• Oxaliplatin (DRUG)
• leucovorin (DRUG)
• Irinotecan (DRUG)
• 5-fluorouracil (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (52 Sites)

Showing the first 25 of 52 sites.

• City of Hope — Duarte, California
• University of California, Los Angeles (UCLA) — Santa Monica, California
• Sarah Cannon Research Institute at HealthOne — Denver, Colorado
• Sibley Memorial Hospital — Washington D.C., District of Columbia
• Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute — Orlando, Florida
• Emory University School of Medicine — Atlanta, Georgia
• Community Health Network — Indianapolis, Indiana
• Massachusetts General Hospital — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
• South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
• New York University (NYU) Langone Medical Center — New York, New York
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
• Duke University Medical Center — Durham, North Carolina
• University of Cincinnati (UC) - Cancer Institute — Cincinnati, Ohio
• Cleveland Clinic — Cleveland, Ohio
• University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center — Pittsburgh, Pennsylvania
• Sarah Cannon Research Institute — Nashville, Tennessee
• USO - US Oncology Research Network — Nashville, Tennessee
• Vanderbilt University School of Medicine — Nashville, Tennessee
• MD Anderson Cancer Center — Houston, Texas
• South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah
• Fred Hutchinson Cancer Center — Seattle, Washington
• University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin

📞 Contact the Study Coordinator

Phone: (317) 615-4559

Email: LillyTrials@Lilly.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pancreatic Ductal Adenocarcinoma

• A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — Rochester, New York
• Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) — Kansas City, Kansas
• Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer — Durham, North Carolina
• Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer — Washington D.C., District of Columbia
• A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma — Philadelphia, Pennsylvania
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma — Los Angeles, California

Explore by condition: All Pancreatic Ductal Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.